Live Chat
0 ITEMS0

0 ITEMS

৳
0
Dhaka

Selected City: Dhaka

Use my current Location


Change City

EN 

|

 বাং

Dhaka

Use my current Location


Change City

Selected City: Dhaka

Grocery
Pharmacy
Cookups
  • Offers
  • Egg Club
  • Daily Deals
  • Favourites
  • Common Conditions 
  • Sexual Wellness
  • Birth Control Contraceptives
  • Vitamins & Supplements 
  • Medical Devices
  • Medical Accessories
  • Personal Care 
  • Health & Wellness 
  • Baby Care 
  • Premium Care
  • Food Aid
  • Recipes
Help
File a complaint

    Telamlo 40/5mg

    10 tablets
    ৳125
    0
    in bag

    Product Information

    TELAMLO

    TelAmlo®  (Telmisartan + Amlodipine)

    Presentation

    TelAmlo 40/5 tablet: Pink, shield shaped, scored on one side,    logo on other side; each tablet contains Telmisartan USP 40mg &

    Amlodipine Besilate BP equivalent to Amlodipine 5mg.

    TelAmlo 80/5 tablet: Pink, diamond shaped, scored on one side,   logo on other side; each tablet contains Telmisartan USP 80mg &

    Amlodipine Besilate BP equivalent to Amlodipine 5mg.

    Indications

    TelAmlo is indicated for the treatment of hypertension alone or with other antihypertensive agents. TelAmlo tablets are indicated

    as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.

    Dosage and Administration

    Initial therapy: The usual starting dose is TelAmlo 40/5 mg once daily. Patients requiring larger blood pressure reductions may be

    started on TelAmlo 80/5 mg once daily. Initial therapy with TelAmlo is not recommended in patients =75 years old or with hepatic

    impairment. Correct imbalances of intravascular volume or salt-depletion, before initiating therapy with TelAmlo tablets. Dosage

    must be individualized and may be increased after at least 2 weeks. Most of the antihypertensive effect is apparent within 2 weeks

    and maximal reduction is generally attained after 4 weeks.

    Replacement therapy: Patients receiving Amlodipine and Telmisartan from separate tablets may instead receive TelAmlo tablets

    containing the same component doses once daily.

    Add-on therapy: TelAmlo tablet may be used to provide additional blood pressure lowering for patients not adequately controlled

    with Amlodipine alone or with Telmisartan alone. Patients treated with 10 mg Amlodipine who experience any dose-limiting adverse

    reactions such as edema, may be switched to TelAmlo 40/5 mg tablets once daily, reducing the dose of Amlodipine without reducing

    the overall expected antihypertensive response.

    Renal impairment: No initial dosage adjustment is required for patients with mild or moderate renal impairment. Titrate slowly in

    patients with severe renal impairment.

    Hepatic impairment: In most patients, initiate Amlodipine therapy at 2.5 mg. Titrate slowly in patients with hepatic impairment.

    Patients 75 years of age and older: In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients 75 years

    of age and older.

    TelAmlo may be taken with or without food.

    Contraindications, warnings etc.

    Contraindication: Hypersensitivity to Telmisartan, Amlodipine, dihydropyridine derivatives or to any of the excipients of TelAmlo.

    Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to

    pregnant women. When pregnancy is detected, discontinue TelAmlo tablets as soon as possible. In patients with an activated renin-

    angiotensin system, such as volume or salt- depleted patients, symptomatic hypotension may occur after initiation of therapy with

    TelAmlo tablets. Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart

    failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt

    substitutes or other drugs that increase potassium levels. Initial therapy with TelAmlo tablets is not recommended in hepatically

    impaired patients. Uncommonly, patients, particularly those with severe obstructive coronary artery disease, have developed

    documented increased frequency, duration or severity of angina or acute myocardial infarction on starting calcium channel blocker

    therapy or at the time of dosage increase. Closely monitor patients with heart failure. Safety and effectiveness of TelAmlo in

    pediatric patients have not been established.

    Warnings: Avoid fetal or neonatal exposure. Hypotension: Correct any volume or salt depletion before initiating therapy. Observe

    for signs and symptoms of hypotension. Titrate slowly in patients with hepatic or severe renal impairment. Heart failure: Monitor

    for worsening. Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker. Myocardial infarction: Uncommonly,

    initiating a CCB in patients with severe obstructive coronary artery disease may precipitate myocardial infarction or increased

    angina.

    Drug Interactions: The pharmacokinetics of Amlodipine and Telmisartan are not altered when the drugs are co-administered. No drug

    interaction studies have been conducted with TelAmlo tablets and other drugs.

    Use in pregnancy and lactation: Pregnancy categories C (first trimester) and D (second and third trimesters). It is not known

    whether Telmisartan and Amlodipine are excreted in human milk. Because of the potential for adverse effects on the nursing infant,

    decide whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

    Adverse reactions: In the placebo-controlled factorial design study, the most common reasons for discontinuation of therapy were

    peripheral edema, dizziness, and hypotension, each leading to discontinuation of =0.5% of patients. Adverse reactions that

    occurred at a =2% higher incidence on Telmisartan/Amlodipine tablets than placebo were peripheral edema (4.8% vs 0%), dizziness

    (3.0% vs 2.2%), clinically meaningful orthostatic hypotension (6.3% vs 4.3%), and back pain (2.2% vs 0%).

    Overdosage: Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with

    telmisartan tablets would be hypotension, dizziness, and tachycardia; bradycardia could occur from parasympathetic stimulation. If

    symptomatic hypotension should occur, supportive treatment should be instituted. Telmisartan is not removed by hemodialysis.

    Overdosage with Amlodipine might be expected to cause excessive peripheral vasodilation with marked hypotension. In humans,

    experience with intentional overdosage of Amlodipine is limited. If massive overdose should occur, active cardiac and respiratory

    monitoring should be instituted. Frequent blood pressure measurements are essential. Should hypotension occur, cardiovascular

    support including elevation of the extremities and the judicious administration of fluids should be initiated. If hypotension

    remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered

    with attention to circulating volume and urine output. Intravenous calcium gluconate may help to reverse the effects of calcium

    entry blockade. As Amlodipine is highly protein bound, hemodialysis is not likely to be of benefit.

    Pharmaceutical Precautions

    Store below 30°C in dry place, protected from light. Keep out of children’s reach.

    Packaging Quantity

    TelAmlo 40/5 tablet: Each pack contains 30 tablets in Alu-Alu blister pack.

    TelAmlo 80/5 tablet: Each pack contains 30 tablets in Alu-Alu blister pack.

    • 30 minute delivery
    • Cash on delivery
    • Pay with

    Chaldal logo

    Chaldal.com is an online shop available in Dhaka, Chattogram, Jashore, Khulna and Narayanganj. We believe time is valuable to our fellow residents, and that they should not have to waste hours in traffic, brave bad weather and wait in line just to buy basic necessities like eggs! This is why Chaldal delivers everything you need right at your door-step and at no additional cost.

    Customer Service

    • Contact Us
    • FAQ

    About Chaldal

    • Privacy Policy
    • Terms of Use

    For Business

    • Corporate
    16710
    or email[email protected]